Prosecution Insights
Prosecution Insights
9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (22%) |
| §103 only | 4 (44%) |
| §112 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDWARDS, LOREN C | 1 | 81.7% | +28.6% |
| HOFFMAN, ALEXANDER JOSEPH | 1 | — | — |
| VANHORN, ABIGAIL LOUISE | 1 | 47.0% | +22.0% |
| KRISHNAN, GANAPATHY | 1 | 52.4% | +0.5% |
| ALABI, OYELEYE A | 1 | 84.3% | +24.7% |
| HAYES, JONATHAN EDWARD | 1 | 37.5% | +23.5% |
| SIMMONS, VALERIE MICHELLE | 1 | 29.5% | +46.2% |
| WHALEY, PABLO S | 1 | 25.3% | +21.3% |
| POHNERT, STEVEN C | 1 | 12.2% | +18.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19367946 | Controlling Intersample Analyte Variability in Complex Biological Matrices | EDWARDS, LOREN C | — |
| 18031713 | Cardiovascular Event Risk Prediction | ALABI, OYELEYE A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17438120 | Reducing Intersample Analyte Variability in Complex Biological Matrices | SIMMONS, VALERIE MICHELLE | 20d |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | — |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | — |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17438120 | Reducing Intersample Analyte Variability in Complex Biological Matrices | SIMMONS, VALERIE MICHELLE | 20d |
| 19367946 | Controlling Intersample Analyte Variability in Complex Biological Matrices | EDWARDS, LOREN C | — |
| 18285736 | Modified Nucleosides | VANHORN, ABIGAIL LOUISE | — |
| 18031713 | Cardiovascular Event Risk Prediction | ALABI, OYELEYE A | — |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | — |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | — |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 3746 | 1 |
| 1636 | 1 |
| 1693 | 1 |
| 1797 | 1 |
| 1685 | 1 |
| 1758 | 1 |
| 3619 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19367946 | Controlling Intersample Analyte Variability in Complex Biological Matrices | EDWARDS, LOREN C | 3746 | §112 | Non-Final OA | — | Pending | Oct 24, 2025 |
| 18693210 | Lung Cancer Prediction and Uses Thereof | HOFFMAN, ALEXANDER JOSEPH | — | §103 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18285736 | Modified Nucleosides | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18477649 | Spin-Labeled Nucleosides and Phosphoramidites | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18031713 | Cardiovascular Event Risk Prediction | ALABI, OYELEYE A | 1797 | §103 | Final Rejection | — | Pending | Apr 13, 2023 |
| 17480698 | Lung Cancer Biomarkers and Uses Thereof | HAYES, JONATHAN EDWARD | 1685 | §101§112 | Non-Final OA | — | Pending | Sep 21, 2021 |
| 17438120 | Reducing Intersample Analyte Variability in Complex Biological Matrices | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Final Rejection | 20d | Pending | Sep 10, 2021 |
| 17297669 | Methods For Determining Disease Risk Combining Downsampling of Class-Imbalanced Sets With Survival Analysis | WHALEY, PABLO S | 3619 | §101§103§112 | Final Rejection | — | Pending | May 27, 2021 |
| 16973734 | IMPROVED PROTEOMIC MULTIPLEX ASSAYS | POHNERT, STEVEN C | 1683 | §103§112 | Final Rejection | — | Pending | Dec 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial